Angle Health raises $200M Series C at $2.7B valuation led by Vitruvian Partners
Angle Health raises a $200M Series C at a $2.7B valuation led by Vitruvian Partners, alongside a $400M tender offer.
Angle Health raises a $200M Series C at a $2.7B valuation led by Vitruvian Partners, alongside a $400M tender offer.
Angle Health has announced a $600 million equity financing at a $2.7 billion valuation: a $200 million Series C and a $400 million tender offer for existing shareholders. Vitruvian Partners led, with new investor Town Hall Ventures and existing investors Blumberg Capital, Portage Ventures, PruVen Capital and Y Combinator. The deal is expected to close later in September.
Founded in 2019 by former Palantir engineers Ty Wang (CEO) and Anirban Gangopadhyay (CTO), the San Francisco company runs an AI-native health benefits platform for small and midsize businesses, covering employers with as few as two staff. Its Benefit Builder tool lets brokers generate underwritten quotes in minutes.
Angle serves more than 5,000 employers across 47 states, reports 120% year-on-year growth and four consecutive profitable quarters, and handles nearly $1 billion in annualised premium-equivalents. The valuation has more than doubled since the $134 million Series B led by Portage in December 2025.
The read: two thirds of the round is secondary. The Wall Street Journal reports the tender priced at $2.5 billion, below the headline.